Efficacy of bevacizumab combined with raltitrexed in the treatment of unresectable hepatocellular carci-noma and its influence on adverse reactions and survival rate
10.3969/j.issn.1006-5725.2024.21.016
- VernacularTitle:贝伐珠单抗联合雷替曲塞治疗不可切除肝细胞癌的疗效及对不良反应和生存率影响
- Author:
Hua WANG
1
;
Yue HEI
;
Miao SUN
;
Yan-Chuang SUN
;
Juan HAN
;
Juanhua SUN
Author Information
1. 空军军医大学第一附属医院肿瘤科(陕西 西安 710032)
- Keywords:
bevacizumab;
Raltitrexed;
unresectable hepatocellular carcinoma;
adverse reactions;
survival rate
- From:
The Journal of Practical Medicine
2024;40(21):3061-3066
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of bevacizumab combined with raltitrexed in the treatment of unresectable hepatocellular carcinoma(HCC)and its effect on adverse reactions and survival rate.Methods A retrospective analysis was performed on 71 patients with unresectable hepatocellular carcinoma admitted to the oncology department of our hospital from February 2020 to June 2022.Among them,35 cases were treated with raltitrexed as control group,and 36 cases were treated with bevacizumab combined with raltitrexed as observation group.All patients received transcatheter arterial chemoembolization(TACE).After 1 month of treatment,the short-term treatment effect of the two groups was evaluated.The adverse reactions of the two groups were observed.Follow-up review was performed to record progression free survival(PFS)and overall survival(OS)in both groups.Results After 1 month of treatment,the disease control rate(DCR)and objective response rate(ORR)of control group were 74.29%and 45.71%respectively.The DCR and ORR of observation group were 83.33%and 55.56%respectively.There was no significant difference in short-term efficacy between the two groups(P>0.05).Following treatment,the vascular endothelial growth factor(VEGF)level in the observation group was considerably lower than in the control group(P<0.05).After treatment,18 months of follow-up,OS curve showed:observation group OS was 50.00%,control group OS was 31.40%;PFS curve showed:observation group PFS was 43.33%,control group PFS was 26.92%.Using the Log-rank test,between the two groups,there was a statistically significant difference in OS(χ2=4.381,P=0.036),although there was no statistically significant difference in PFS between the two groups(χ2=3.264,P=0.071).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion Bevacizumab combined with raltitrexed can reduce tumor neovascularization,inhibit tumor growth and spread,prolong the survival time of patients,and do not increase adverse drug reactions.
